Congress Program
08:00-08:50
Registration
08:50-09:00
Congress Opening & Welcome
Dr. Silviu Brill, Israel and Prof. David Finn, Ireland | Congress Chairs
09:00-10:00
Session 1: Full Spectrum Cannabis
09:00-09:25
Anti-inflammatory effects of cannabis: from fundamental mechanisms to applications
Olga Kovalchuk
University of Lethbridge, Canada
09:25-09:50
Cannabis Effects Depend on Age
Andras Bilkei-Gorzo
University Hospital Bonn, Germany
09:50-10:00
Discussion/Q&A
10:00-10:30
Panel Discussion
10:00-10:30
What is the best way to treat chronic pain with cannabinoids?
Silviu Brill
Tel Aviv Medical Center, Israel
Thomas R. Tölle
Technical University of Munich, Germany
Haggai Sharon
Tel Aviv Medical Center, Israel
Miri Ogintz
Rambam Health Care Campus, Israel
10:30-11:00
Coffee Break, Poster Viewing and Visit the Exhibition
11:00-12:30
Session 2: Single Molecules
11:00-11:25
Anti-inflammatory potential of components of Cannabis sativa L. with relevance to multiple sclerosis pathogenesis
Eric Downer
Trinity College Dublin, Ireland
11:25-11:50
The “invisible” disability: chronic pain - therapeutic potential of endocannabinoids
Katarzyna Starowicz
Maj Institute of Pharmacology, Academy of Sciences, Poland
11:50-12:15
Endocannabinoid System modulation and Autism Spectrum Disorder: evidence from preclinical studies
Michelle Roche
University of Galway, Ireland
12:15-12:30
Discussion/Q&A
12:30-13:30
Lunch Break, Poster Viewing and Visit the Exhibition
13:30-15:00
Session 3: Research and Clinical Practice in Germany
13:30-13:55
The DISCOVER studies in Germany and Austria: the path to evidence for cannabinoids in the treatment of chronic pain
Thomas R. Tölle
Technical University of Munich, Germany
13:55-14:20
Anti-Ageing Effect of THC Treatment
Andras Bilkei-Gorzo
University Hospital Bonn, Germany
14:20-14:45
Industry Lecture: Overview of a patient-centred holistic medical cannabis treatment platform in Germany
Julian Wichmann
Algea Care, Germany
14:45-15:00
Discussion/Q&A
15:00-15:30
Coffee Break, Poster Viewing and Visit the Exhibition
15:30-16:30
Session 4: Updates on Status of Medical Cannabis and Cannabinoids in Other European Countries
15:30-15:40
United Kingdom
Anne Katrin Schlag
King's College London, UK
15:40-15:50
Israel
Silviu Brill
Tel Aviv Medical Center, Israel
15:50-16:00
Italy
Livio Luongo
University of Campania “L. Vanvitelli”, Italy
16:00-16:10
Poland
Anita Jeglinska
Polish Association of Cannabis Therapies, Poland
16:10-16:30
Panel Discussion
16:30
End of Day One
08:30-09:00
Registration
09:00-10:30
Session 5: Clinical Advice to Patients
09:00-09:25
A global overview of medical cannabis guidance and resources: current limitations and potential pathways forward
Myfanwy Graham
University of Newcastle, Australia
09:25-09:50
Pain Management - Rules and Tools for Medical Cannabis
Miri Ogintz
Rambam Health Care Campus, Israel
09:50-10:15
Effective and Safe Digital Health Platforms for Managing Medical Cannabis Patients
Itay Goor Aryeh
Sheba Medical Center, Israel
10:15-10:30
Discussion/Q&A
10:30-11:00
Coffee Break, Poster Viewing and Visit the Exhibition
11:00-12:30
Session 6: Co-Morbidities - Preclinical & Clinical
11:00-11:25
Interactions between pain, negative affect and cognition: role of the endocannabinoid system
David Finn
University of Galway, Ireland
11:25-11:50
Endogenous N-acylethanolamines regulates the chronic pain-associated depressive and cognitive impairments
Livio Luongo
University of Campania “L. Vanvitelli”, Italy
11:50-12:15
Is Medical Cannabis Safe for my Patient - Balancing Harm and Benefit
Haggai Sharon
Tel Aviv Medical Center, Israel
12:15-12:40
Real world data on prescribed cannabis use in Project Twenty21 (T21): A focus on co-morbidities
Anne Katrin Schlag
King's College London, UK
12:40-12:50
Discussion/Q&A
12:50-13:50
Lunch Break, Poster Viewing and Visit the Exhibition
13:50-15:00
Guided Poster Walk Session
Moderators: Dr. Silviu Brill, Israel and Prof. David Finn, Ireland
15:00-15:30
Coffee Break, Poster Viewing and Visit the Exhibition
15:30-17:00
Industry Session: Novel Drugs Targeting the Endocannabinoid System
15:30-15:55
A Novel Cannabidiol:Tetramethylpyrazine (CBD:TMP, ART12.11) Cocrystal Improves the Bioavailability and Efficacy of CBD
George Warren
Artelo Biosciences, United Kingdom
15:55-16:20
Snapshots on the Discovery and Development of Cannabinoid Receptor Type 2 Agonist RG7774
Uwe Grether
F. Hoffmann-La Roche, Switzerland
16:20-16:45
The Hurdles to Market – Regulatory and Clinical Trial Considerations in Europe
Heike Schön
Lumis International, Germany
Liam Spencer
Lumis Life Science, Germany
16:45-17:00
Discussion/Q&A & Congress Closing Remarks
17:00
Congress Closing
Dr. Silviu Brill, Israel and Prof. David Finn, Ireland | Congress Chairs
